PhRMA Wades Into FDA Patient-Focused Data Collection: Website Systems for Crowd-Sourced Info
This article was originally published in RPM Report
Trade association partners with Genetic Alliance to provide input into FDA drug development initiative. That may be an effective intervention by PhRMA as it experiments with new ways to shape regulatory policy beyond traditional advocacy efforts.
You may also be interested in...
FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.
The new Prescription Drug User Fee Act Program doesn’t take effect until October 1, but FDA has been getting moving on some key elements of the program since before the final negotiations began on Capitol Hill. FDA will need to move fast to meet the many policy deadlines set by the agreement negotiated with industry.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.